Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study

BACKGROUND: Intravenous infusion of ketamine can produce rapid and large symptom reduction in patients with treatment-resistant depression (TRD) but presents major obstacles to clinical applicability, especially in community settings. Oral esketamine may be a promising addition to our TRD treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith-Apeldoorn, Sanne Y., Veraart, Jolien K. E., Ruhé, Henricus G., aan het Rot, Marije, Kamphuis, Jeanine, de Boer, Marrit K., Schoevers, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693908/
https://www.ncbi.nlm.nih.gov/pubmed/34865676
http://dx.doi.org/10.1192/bjo.2021.1059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693908/
https://www.ncbi.nlm.nih.gov/pubmed/34865676
http://dx.doi.org/10.1192/bjo.2021.1059

Ejemplares similares